2020 Year in Review - Breast Cancer
2020 Year in Review - Breast Cancer | January 25, 2021
In this real-world retrospective study, more patients in the ribociclib cohort compared with palbociclib and abemaciclib maintained starting doses and fewer patients decreased to 50% of the starting dose.
2020 Year in Review - Breast Cancer | January 25, 2021
Real-world data showed that patients with metastatic breast cancer receiving palbociclib had a numerically higher rate of neutropenia than patients receiving ribociclib.